{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:14:39Z","timestamp":1789802079007,"version":"4.0.1"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the barriers to guideline-directed medical therapy (GDMT) use in heart failure (HF), diagnostic workup and general knowledge about HF among physicians in Sweden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A survey about the management of HF was sent to 828 Swedish physicians including general practitioners (GPs) and specialists during 2021\u20132022. Answers were reported as percentages and comparisons were made by specialty (GPs vs. specialists).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred sixty-eight physicians participated in the survey (40% females, median age 43 years; 41% GPs and 59% specialists). Electrocardiography and New York Heart Association class evaluations are mostly performed once a year by GPs (46%) and at every outpatient visit by specialists (40%). Echocardiography is mostly requested if there is clinical deterioration (60%). One-third of participants screen for iron deficiency only if there is anemia. Major obstacles to implementation of different drug classes in HF with reduced ejection fraction are related to side effects, with no significant differences between specialties. Device implantation is deemed appropriate regardless of aetiology (69%) and patient age (86%). Specialists answered correctly to knowledge questions more often than GPs. Eighty-six percent of participants think that GDMT should be implemented as much as possible. Most participants (57%) believe that regular patient assessment in nurse-led HF clinics improve adherence to GDMT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Obstacles to GDMT implementation according to physicians in Sweden mainly relate to potential side effects, lack of specialist knowledge and organizational aspects. Further efforts should be placed in educational activities and structuring of nurse-led clinics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1385281","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T04:58:53Z","timestamp":1715662733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The management of heart failure in Sweden\u2014the physician\u2019s perspective: a survey"],"prefix":"10.3389","volume":"11","author":[{"given":"Giulia","family":"Ferrannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia Emanuele","family":"Biber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"St\u00e5hlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Rocca HP","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish heart failure registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.119.043012","article-title":"Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish heart failure registry","volume":"140","author":"Schrage","year":"2019","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish heart failure registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1002\/ehf2.12883","article-title":"Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants","volume":"7","author":"Fu","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2131","article-title":"Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish heart failure registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.2483","article-title":"Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata","volume":"24","author":"Stolfo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ejhf.2798","article-title":"Personalized care of patients with heart failure: are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals\u2019 needs and patients\u2019 perceptions","volume":"25","author":"Jankowska","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/ejhf.2644","article-title":"Trajectories in New York heart association functional class in heart failure across the ejection fraction spectrum: data from the Swedish heart failure registry","volume":"24","author":"Lindberg","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York heart association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ejhf.2778","article-title":"Use of patient-reported outcomes in heart failure: from clinical trials to routine practice","volume":"25","author":"Savarese","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cardfail.2022.07.047","article-title":"Guideline-Directed medical therapy in newly diagnosed heart failure with reduced ejection fraction in the community","volume":"28","author":"Dunlay","year":"2022","journal-title":"J Card Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ejhf.2892","article-title":"Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population","volume":"25","author":"Musella","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e011737","DOI":"10.1161\/JAHA.118.011737","article-title":"Nurse-led heart failure clinics are associated with reduced mortality but not heart failure hospitalization","volume":"8","author":"Savarese","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ejhf.765","article-title":"Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis","volume":"19","author":"Van Spall","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/ehf2.13848","article-title":"Patient profile and outcomes associated with follow-up in specialty vs. Primary care in heart failure","volume":"9","author":"Lindberg","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ejhf.762","article-title":"Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study","volume":"19","author":"Lund","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/europace\/eut416","article-title":"Awareness of indications for device therapy among a broad range of physicians: a survey study","volume":"16","author":"Hubinette","year":"2014","journal-title":"Europace"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","article-title":"Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis","volume":"104","author":"Beggs","year":"2018","journal-title":"Heart"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jcmg.2016.01.033","article-title":"Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis","volume":"9","author":"Disertori","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ejhf.496","article-title":"Use of evidence-based therapy and survival in heart failure in Sweden 2003\u20132012","volume":"18","author":"Thorvaldsen","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.1615","article-title":"Association between beta-blocker use and mortality\/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish heart failure registry","volume":"22","author":"Stolfo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/ejhf.1799","article-title":"Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF","volume":"23","author":"Mordi","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","article-title":"Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study","volume":"39","author":"Savarese","year":"2018","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e004745","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","article-title":"Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ejhf.2477","article-title":"Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish heart failure registry","volume":"24","author":"D'Amario","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the working group on cardiovascular pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40273-018-0709-3","article-title":"Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia","volume":"36","author":"Bounthavong","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician\u2019s prescriptions to patient\u2019s dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","article-title":"Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish heart failure registry and the Stockholm CREAtinine measurements collaborative project","volume":"25","author":"Lindberg","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jchf.2023.11.006","article-title":"Meta-Analysis and metaregression of the treatment effect of intravenous iron in iron-deficient heart failure","volume":"12","author":"Martens","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ejhf.2743","article-title":"Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European society of cardiology guidelines: an international cardiology survey","volume":"25","author":"Fauvel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ejhf.2928","article-title":"Association between a hospitalization for heart failure and the initiation\/discontinuation of guideline-recommended treatments: an analysis from the Swedish heart failure registry","volume":"25","author":"Schrage","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee","volume":"83","author":"Writing","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.jacadv.2023.100743","article-title":"Underrepresentation of women in reduced ejection heart failure clinical trials with improved mortality or hospitalization","volume":"3","author":"Ekpo","year":"2024","journal-title":"JACC Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/jcm11051176","article-title":"Update on management of cardiovascular diseases in women","volume":"11","author":"Luca","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1385281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T04:59:01Z","timestamp":1715662741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1385281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":54,"alternative-id":["10.3389\/fcvm.2024.1385281"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1385281","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"article-number":"1385281"}}